Company: ABUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001447028-25-000115
Chunk: 18

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
0252024RevenueCollaborations and licenses$10,213 $1,155 $11,529 $2,094 Non-cash royalty revenue526 571 974 1,164 Total Revenue10,739 1,726 12,503 3,258 Operating expenses Research and development5,498 15,551 14,457 30,954 General and administrative3,328 7,547 9,160 12,859 Change in fair value of contingent consideration260 211 559 391 Restructuring costs165 — 12,538 — Total operating expenses9,251 23,309 36,714 44,204 Gain (loss) from operations1,488 (21,583)(24,211)(40,946)Other incomeInterest income1,042 1,829 2,239 3,374 Interest expense(28)(34)(56)(78)Foreign exchange gain (loss)21 (8)25 (21)Total other income1,035 1,787 2,208 3,275 Net income (loss)$2,523 $(19,796)$(22,003)$(37,671)Net income (loss) per common share  Basic$0.01 $(0.11)$(0.12)$(0.21)Diluted$0.01 $(0.11)$(0.12)$(0.21)Weighted average number of common shares  Basic191,551,282 188,041,489 191,130,631 181,842,519 Diluted192,399,733 188,041,489 191,130,631 181,842,519 Comprehensive income (loss)Unrealized (loss) gain on available-for-sale securities$(21)$63 $(52)$113 Comprehensive income (loss)$2,502 $(19,733)$(22,055)$(37,558)

See accompanying notes to the condensed consolidated financial statements.

2

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31,